TW274550B - - Google Patents

Info

Publication number
TW274550B
TW274550B TW082107380A TW82107380A TW274550B TW 274550 B TW274550 B TW 274550B TW 082107380 A TW082107380 A TW 082107380A TW 82107380 A TW82107380 A TW 82107380A TW 274550 B TW274550 B TW 274550B
Authority
TW
Taiwan
Prior art keywords
formula
image
substituents
compounds
action against
Prior art date
Application number
TW082107380A
Other languages
English (en)
Chinese (zh)
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of TW274550B publication Critical patent/TW274550B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW082107380A 1992-09-26 1993-09-09 TW274550B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232392 1992-09-26

Publications (1)

Publication Number Publication Date
TW274550B true TW274550B (en:Method) 1996-04-21

Family

ID=6468974

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082107380A TW274550B (en:Method) 1992-09-26 1993-09-09

Country Status (20)

Country Link
US (1) US5424311A (en:Method)
EP (1) EP0590428B1 (en:Method)
JP (1) JPH06211855A (en:Method)
KR (1) KR940007035A (en:Method)
AT (1) ATE187724T1 (en:Method)
AU (1) AU664643B2 (en:Method)
CA (1) CA2106882C (en:Method)
CZ (1) CZ9302005A3 (en:Method)
DE (1) DE59309902D1 (en:Method)
DK (1) DK0590428T3 (en:Method)
ES (1) ES2141744T3 (en:Method)
GR (1) GR3032520T3 (en:Method)
HU (1) HUT65302A (en:Method)
IL (1) IL107081A (en:Method)
MX (1) MX9305894A (en:Method)
NZ (1) NZ248762A (en:Method)
PH (1) PH30348A (en:Method)
PT (1) PT590428E (en:Method)
TW (1) TW274550B (en:Method)
ZA (1) ZA937081B (en:Method)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620978A (en) * 1994-01-03 1997-04-15 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
CN1184895C (zh) 1998-07-16 2005-01-19 阿龙·塔博尔 大豆组合物及其促进健康的应用
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
HRP20090036T3 (en) * 2003-05-23 2009-03-31 Æterna Zentaris Gmbh Novel pyridopyrazines and use thereof as kinase modulators
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
KR101061328B1 (ko) * 2006-04-21 2011-08-31 화이자 프로덕츠 인크. 피리딘[3,4-ｂ]피라지논
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0614471D0 (en) * 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
ES2381215T3 (es) * 2006-10-19 2012-05-24 Signal Pharmaceuticals Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
EP2078018B1 (en) * 2006-10-19 2012-03-14 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
US8372114B2 (en) * 2006-11-13 2013-02-12 Electroformed Stents, Inc. Over-the-wire exclusion device and system for delivery
JP5261487B2 (ja) * 2007-08-03 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン誘導体の結晶形
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
TWI557117B (zh) 2008-12-09 2016-11-11 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
EA020301B1 (ru) * 2009-01-23 2014-10-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы поли(адф-рибозо)полимеразы (parp)
JP5715625B2 (ja) 2009-07-30 2015-05-07 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
NZ598384A (en) * 2009-09-14 2014-04-30 Gilead Sciences Inc Modulators of toll-like receptors
KR101903925B1 (ko) 2009-10-26 2018-10-02 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
ES2670659T3 (es) * 2010-02-03 2018-05-31 Signal Pharmaceuticals, Llc Identificación de mutación en LKB1 como un biomarcador predictivo para la sensibilidad a inhibidores de la quinasa TOR
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
MX373925B (es) 2011-10-19 2020-07-10 Signal Pharm Llc Tratamiento del cancer con inhibidores de tor cinasa.
JP2015501793A (ja) 2011-11-10 2015-01-19 オーエスアイ・ファーマシューティカルズ，エルエルシー ジヒドロプテリジノン類
ES2694413T3 (es) 2011-12-02 2018-12-20 Signal Pharmaceuticals, Llc Composiciones farmacéuticas de 7-(6-(2-hidroxipropan-2-il)piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino [2,3-b]pirazin-2(1H)-ona, una forma sólida de la misma y métodos para su uso
MX358303B (es) 2012-02-24 2018-08-14 Signal Pharm Llc Uso de 7-(6-(2-hidroxipropan-2il) piridin-3-il)-1-((1r,4r)4-metoxi ciclohexil)-3, 4-dihidropirazin-[2,3-b] pirazin-2(1h)-ona o una sal, estereoisómero o tautómero aceptable farmaceuticamente del mismo, en combinación con una cantidad efectiva de erlotinib o azacitidina para preparar un composición farmacéutica en el tratamiento de cáncer de pulmón de cédula no pequeña, avanzado.
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN105188704B (zh) 2013-01-16 2017-09-19 西格诺药品有限公司 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
KR20160002792A (ko) 2013-04-17 2016-01-08 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법
TWI631950B (zh) 2013-04-17 2018-08-11 標誌製藥公司 藉二氫吡𠯤并吡𠯤治療癌症
MX368286B (es) 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
HK1221951A1 (zh) 2013-04-17 2017-06-16 西格诺药品有限公司 有關1-乙基-7-(2-甲基-6-(1H-1，2，4-三唑-3-基)吡啶-3-基)-3，4-二氫吡嗪並[2，3-b]吡嗪-2(1H)-酮的藥物製劑、程序、固體形式和使用方法
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
HK1221144A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治療癌症的包含tor激酶抑制劑和胞苷類似物的組合療法
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
EP3003313A1 (en) 2013-05-29 2016-04-13 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
CA2954056C (en) 2014-07-11 2020-04-28 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CA2955009A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US9573952B2 (en) 2014-09-16 2017-02-21 Gilead Sciences, Inc. Methods of preparing toll-like receptor modulators
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
KR102272284B1 (ko) * 2020-01-13 2021-07-02 금오공과대학교 산학협력단 정밀 압력제어가 가능한 다단 스프링 압력제어밸브
TW202523311A (zh) * 2023-10-16 2025-06-16 美商克洛諾斯生技有限公司 離胺酸乙醯基轉移酶抑制劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
GR72941B (en:Method) * 1978-10-20 1984-01-16 Lilly Co Eli
IE58312B1 (en) * 1984-05-18 1993-09-08 Union Pharma Scient Appl Heterocyclic derivatives, processes for their preparation and drugs in which they are present, which are useful especially as aldose reductase inhibitors
JPH0276860A (ja) * 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
DK160876C (da) * 1987-12-08 1991-10-14 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar
EP0509398B1 (de) * 1991-04-15 2001-09-19 Aventis Pharma Deutschland GmbH Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
CA2106882A1 (en) 1994-03-27
AU4755393A (en) 1994-03-31
EP0590428A1 (de) 1994-04-06
CZ9302005A3 (en) 1994-04-13
HUT65302A (en) 1994-05-02
DK0590428T3 (da) 2000-05-22
IL107081A (en) 1999-07-14
JPH06211855A (ja) 1994-08-02
CA2106882C (en) 2007-04-17
ZA937081B (en) 1994-04-18
HU9302696D0 (en) 1993-12-28
KR940007035A (ko) 1994-04-26
DE59309902D1 (de) 2000-01-20
PT590428E (pt) 2000-04-28
NZ248762A (en) 1996-01-26
PH30348A (en) 1997-04-02
US5424311A (en) 1995-06-13
EP0590428B1 (de) 1999-12-15
ES2141744T3 (es) 2000-04-01
MX9305894A (es) 1994-03-31
AU664643B2 (en) 1995-11-23
GR3032520T3 (en) 2000-05-31
IL107081A0 (en) 1993-12-28
ATE187724T1 (de) 2000-01-15

Similar Documents

Publication Publication Date Title
TW274550B (en:Method)
PH30006A (en) 9-¬(Substituted glycol)amido¾-6.demethyl-6-deoxytetra-cyclines
TW234120B (en:Method)
TW207533B (en:Method)
ATE169637T1 (de) Derivate des dolastatin
PH31682A (en) 4-Iminoquinolines, process for their preparation, and their use.
AU3196293A (en) Heteroaryl substituted biphenylmethyl benzimidazoles
JPS57144278A (en) Dibenzofuran derivative, manufacture and bactericide containing same as effective component
IL65756A0 (en) N-substituted 2-methylnaphthylamides,their preparation and their use as fungicides
ZA887158B (en) Azachromane derivatives
GR74782B (en:Method)
DK0584653T3 (en:Method)
DE59405727D1 (de) Thiocarbamoylverbindungen als mikrobizide
ES8703847A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinopirimidina
ES8703855A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinotriazina
ZA874596B (en) 3-substituted 1-(2-halogenoalkoxy-benzenesulphonyl)-3-heteroaryl-(thio)ureas
CA2195663A1 (en) Dihydrobenzofuranes